CTNI-57. MATRix REGIMEN FOR NEWLY DIAGNOSED PRIMARY DIFFUSE B-CELL LYMPHOMA OF THE CENTRAL NERVOUS SYSTEM

Abstract We report our experience treating 20 patients with newly diagnosed primary diffuse B-cell lymphoma of the central nervous system MATRix regimen as reported by Ferreri, et al in 2016. The median age was 65 y; 8 were men and 12 women. Eighteen had cerebral mass lesions, 1 a paraspinal mass, leptomeningeal disease. Treatment consisted 4 cycles rituximab 375 mg/sq m (Days 1, 6); methotrexate 3.5 g/sq (Day 2); cytarabine 2 every h 3, 4); thiotepa 30 5). Patients without disease progression received carmustine 400 5 mg/kg followed autologous bone marrow transplantation. Four switched to after 6 only initial including thiotepa. Overall, 14 completed chemotherapy. Twelve these went on transplantation; one patient early progression, no stem cells could be collected. All over 70 y died 1-2 cycles; 80 y, causes death neutropenic fever, septic thrombophlebitis, cardiac arrest. One who entire transplantation fungal pneumonia; other 13 experienced serious acute toxicity. late progression; developed symptomatic leukoencephalopathy. Thirteen remain alive. Median OS for cohort is 698 days. These preliminary data suggest that safe highly effective setting. However, high incidence suggests may too toxic elderly individuals.